Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Shift Technologies to Perform

Oppenheimer Downgrades Shift Technologies to Perform

Oppenheimer analyst Brian Nagel downgrades Shift Technologies (NASDAQ:SFT) from Outperform to Perform.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Oppenheimer analyst Brian Nagel downgrades Shift Technologies (NASDAQ:SFT) from Outperform to Perform.

Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $17

By Benzinga Newsdesk

December 7, 12:50 PM

Chardan Capital analyst Geulah Livshits maintains Achilles Therapeutics (NASDAQ:ACHL) with a Buy and lowers the price target from $20 to $17.

ACHL

SVB Leerink Maintains Outperform on Prometheus Biosciences, Raises Price Target to $60

By Benzinga Newsdesk

August 12, 5:06 AM

SVB Leerink analyst Thomas Smith maintains Prometheus Biosciences (NASDAQ:RXDX) with a Outperform and raises the price target from $55 to $60.

RXDX

Nike Has ‘Stronger Revenue Growth Ahead,’ Says Bullish Goldman Sachs

By Priya Nigam

December 5, 12:40 PM

Nike Inc (NYSE: NKE) offered heavy discounts, going up to 60% on even fresh stock, during Black Friday and Cyber Monday as bargain-conscious shoppers increased t

NKE

Analyst Ratings

Analyst Expectations for MercadoLibre’s Future

By Benzinga Insights

May 2, 3:01 PM

Over the past 3 months, 7 analysts have published their opinion on MercadoLibre (NASDAQ:MELI) stock. These analysts are…

MELI

Oppenheimer Downgrades Shift Technologies to Perform

Related Posts

Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $17

SVB Leerink Maintains Outperform on Prometheus Biosciences, Raises Price Target to $60

Nike Has ‘Stronger Revenue Growth Ahead,’ Says Bullish Goldman Sachs

Analyst Expectations for MercadoLibre’s Future